Average LOS of patient with HAIs, n (IQR),95%CI | Average LOS of patient with no HAIs n (IQR),95%CI | Extra LOS of patient with HAIs, n | Extra cost of therapy caused by HAIs | |
---|---|---|---|---|
One infection | 21(14–33),95%CI(27.72–28.7) | 6.0 (3–11),95%CI(8.27–9.42) | 15 | US$ 11,475 € 10,035 |
Multiple infections | 39.5(31–51),95%CI(35.68–49.41) | 6.0 (3–11),95%CI(8.27–9.42) | 33.5 | US$ 25,627 € 22,411.5 |
VAP | 27(15–41),95%CI(26.77–34.39) | 6.0 (3–11),95%CI(8.27–9.42) | 21 | US$ 16,065 € 14,049 |
CLA-BSI | 30(20–43),95%CI(23.13–38.59) | 6.0 (3–11),95%CI(8.27–9.42) | 24 | US$ 18,360 € 16,056 |
CA-UTI | 29.00(14.5–43.5),95%CI(26.69–35.76) | 6.0 (3–11),95%CI(8.27–9.42) | 23 | US$ 17,595 € 15,387 |
Additional cost of therapy in observed period | US$ 1413,480 /1 year € 1236,378 /1 year |